[1] |
World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
|
[2] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[3] |
中华医学会结核病学分会, 利奈唑胺抗结核治疗专家共识编写组. 利奈唑胺抗结核治疗专家共识. 中华结核和呼吸杂志, 2018,41(1):14-19.
|
[4] |
Kanafani ZA, Corey GR . Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs, 2012,21(4):515-522.
|
[5] |
中国防痨协会基础专业委员会. 结核病诊断实验室检验规程. 北京: 中国教育文化出版社, 2006.
|
[6] |
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014.
|
[7] |
Pang Y, Zong Z, Huo F , et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid,clofazimine,moxifloxacin,gatifloxacin against extensively drug-resistant tuberculosis in Beijing,China. Antimicrob Agents Chemother, 2017, 61(10).pii:e00900-17.
|
[8] |
Vera-Cabrera L, Brown-Elliott BA, Wallace RJ Jr , et al. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother, 2006,50(12):4027-4029.
|
[9] |
宗兆婧, 荆玮, 霍凤敏 , 等. 广泛耐药结核分枝杆菌对利奈唑胺的耐药情况分析. 新发传染病电子杂志, 2017,2(3):160-163.
|
[10] |
Yang JS, Kim KJ, Choi H , et al. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med, 2018,38(6):563-568.
|
[11] |
王前, 宋媛媛, 王玉峰 , 等. 158株耐多药结核分枝杆菌对利奈唑胺耐药及相关基因突变情况研究. 中国防痨杂志, 2016,38(9):712-717.
|
[12] |
廖传玉, 李同心, 陈天刚 , 等. 特雷唑来对结核分枝杆菌体外抑菌作用的初步研究. 临床肺科杂志, 2017,22(7):1169-1172.
|
[13] |
Ruiz P, Causse M, Vaquero M , et al. In vitro activity of tedizolid against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019, 63(4). pii:e01939-18.
|
[14] |
黄海荣, 于霞, 姜广路 , 等. 利奈唑胺对分枝杆菌体外抑菌作用的初步研究. 中华结核和呼吸杂志, 2011,34(8):575-578.
|